🇪🇺 Reblozyl in European Union

EMA authorised Reblozyl on 25 June 2020

Marketing authorisation

EMA — authorised 25 June 2020

  • Application: EMEA/H/C/004444
  • Marketing authorisation holder: Bristol Myers Squibb Pharma EEIG
  • Local brand name: Reblozyl
  • Indication: Reblozyl is indicated in adults for the treatment of transfusion-dependent anaemia due to very low, low and intermediate-risk myelodysplastic syndromes (MDS).Reblozyl is indicated in adults for the treatment of anaemia associated with transfusion dependent and non transfusion dependent beta thalassaemia.  Reblozyl is indicated in adults for the treatment of transfusion-dependent anaemia due to very low, low and intermediate-risk myelodysplastic syndromes (MDS).Reblozyl is indicated in adults for the treatment of anaemia associated with transfusion dependent and non transfusion dependent b
  • Pathway: orphan
  • Status: approved

Read official source →

Reblozyl in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Other approved in European Union

Frequently asked questions

Is Reblozyl approved in European Union?

Yes. EMA authorised it on 25 June 2020.

Who is the marketing authorisation holder for Reblozyl in European Union?

Bristol Myers Squibb Pharma EEIG holds the EU marketing authorisation.